Regeneron Pharmaceuticals (STU:RGO) Shares Outstanding (EOP): 105 Mil (As of Mar. 2026)


STU:RGO Regeneron Pharmaceuticals Inc STU:RGO
89 GF Score
Price €592.50
GF Value €790.59
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Shares Outstanding (EOP)?

Regeneron Pharmaceuticals STU:RGO +4.30% 89 Shares Outstanding (EOP) is 105 Mil as of Mar. 2026. GuruFocus rates STU:RGO with a GF Score™ of 89/100 and a GF Value™ of €790.59 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Regeneron Pharmaceuticals's shares outstanding for the quarter that ended in Mar. 2026 was 105 Mil.

Regeneron Pharmaceuticals's quarterly shares outstanding declined from Dec. 2025 (106 Mil) to Mar. 2026 (105 Mil). It means Regeneron Pharmaceuticals bought back shares from Dec. 2025 to Mar. 2026 .

Regeneron Pharmaceuticals's annual shares outstanding declined from Dec. 2024 (110 Mil) to Dec. 2025 (106 Mil). It means Regeneron Pharmaceuticals bought back shares from Dec. 2024 to Dec. 2025 .


Regeneron Pharmaceuticals  (STU:RGO) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Regeneron Pharmaceuticals Shares Outstanding (EOP) Related Terms


Regeneron Pharmaceuticals Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Shares Outstanding (EOP) Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 108.68 109.60 109.42 109.62 105.72

Regeneron Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.22 106.42 105.32 105.72 105.02

STU:RGO vs ALNY, RVMD, ONC: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Shares Outstanding (EOP) falls into.


STU:RGO
89GF Score
Regeneron Pharmaceuticals Inc STU:RGO
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 105 Mil mean?
Regeneron Pharmaceuticals (STU:RGO) has a Shares Outstanding (EOP) of 105 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Shares Outstanding (EOP) too high?
Regeneron Pharmaceuticals' current Shares Outstanding (EOP) is 105 Mil. Overall, Regeneron Pharmaceuticals has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Shares Outstanding (EOP) compare to ALNY and RVMD?
Regeneron Pharmaceuticals' Shares Outstanding (EOP) of 105 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Shares Outstanding (EOP) is 105 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Modestly Undervalued. The stock's GF Value™ is €790.59, compared to a current price of €592.50 — trading 25.1% below its estimated fair value. The current Shares Outstanding (EOP) is 105 Mil. Regeneron Pharmaceuticals' overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current Shares Outstanding (EOP) is 105 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of €592.50 is trading 25.1% below its estimated GF Value™ of €790.59. GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for STU:RGO:

  • Shares Outstanding (EOP): 105 Mil
  • GF Value™: €790.59 vs. price of €592.50 (25.1% below fair value)
  • GF Score™: 89/100 with 3 warning signs

No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
89GF Score

Get the complete analysis for STU:RGO

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€592.50
Price
€790.59
GF Value